reference/25817505

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/25817505

Outgoing Links

Predicate	Object
contentType	Journal Article\|Research Support, Non-U.S. Gov't
endingPage	20
issn	0167-6997 1573-0646
issueIdentifier	1
pageRange	10-20
publicationName	Investigational New Drugs
startingPage	10
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_855276b36d1ea379d6a73dab5b988d0d
bibliographicCitation	Xue X, Zhang Y, Liao Y, Sun D, Li L, Liu Y, Wang Y, Jiang W, Zhang J, Luan Y, Zhao X. Design, synthesis and biological evaluation of dual HDAC and VEGFR inhibitors as multitargeted anticancer agents. Invest New Drugs. 2022 Feb;40(1):10–20. doi: 10.1007/s10637-021-01169-4. PMID: 34463890.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_95414a47d928e2c42043adb245a2548b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_921175297329592d778de8caf05110bd http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_96d5d63b396a7fb8d70aaaab2c01a2ca http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d6e9f33ef5e20567ccfe64b1c55c2413 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2ae014e357bf0f97737849baba6765f5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-6230-709X http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_73f0413e2577eec5fc7fc1e60b9a5043 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_74f024959e55ac02756cdf6c67455a4e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e50ec062666bdd5d7c3a8d87f328acb5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7307852ec4a65733f667922e16452a34 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_40a2d82c8d34c223b4eec5d0f164fdb6
date	2021-08-31^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1007/s10637-021-01169-4 https://pubmed.ncbi.nlm.nih.gov/34463890
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/4372 https://portal.issn.org/resource/ISSN/1573-0646 https://portal.issn.org/resource/ISSN/0167-6997
language	English
source	https://scigraph.springernature.com/ https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Design, synthesis and biological evaluation of dual HDAC and VEGFR inhibitors as multitargeted anticancer agents
discusses	http://id.nlm.nih.gov/mesh/M0011208 http://id.nlm.nih.gov/mesh/M0506157 http://id.nlm.nih.gov/mesh/M0020790 http://id.nlm.nih.gov/mesh/M0288128 http://id.nlm.nih.gov/mesh/M0328153 http://id.nlm.nih.gov/mesh/M0010739 http://id.nlm.nih.gov/mesh/M0018260 http://id.nlm.nih.gov/mesh/M0527853 http://id.nlm.nih.gov/mesh/M0057221
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D056572Q000494 http://id.nlm.nih.gov/mesh/D006877Q000494 http://id.nlm.nih.gov/mesh/D020533Q000494 http://id.nlm.nih.gov/mesh/D042442Q000037
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D007191Q000494 http://id.nlm.nih.gov/mesh/D013449Q000494 http://id.nlm.nih.gov/mesh/D011743Q000494 http://id.nlm.nih.gov/mesh/D015195 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D051381 http://id.nlm.nih.gov/mesh/D061307 http://id.nlm.nih.gov/mesh/D017207 http://id.nlm.nih.gov/mesh/D000818 http://id.nlm.nih.gov/mesh/D008862 http://id.nlm.nih.gov/mesh/D000077337Q000494 http://id.nlm.nih.gov/mesh/D051379 http://id.nlm.nih.gov/mesh/D045744
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4261 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10113978 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_5b5372f26c262665d7f5b3f48d85941e http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5311 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_cb58e6788fc9a69c674bb00f98bffc14 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_31276be7cbfc21f211d5837baf0250cd http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_3.5.1.98

Showing number of triples: 1 to 66 of 66.